Eirion Therapeutics Announces Strategic Agreement with HTL Biotechnology
Sep 08, 2021, 09:00 ET Eirion Therapeutics Announces Strategic Agreement for HTL Biotechnology to Become Eirion’s Exclusive Botulinum API Manufacturer WOBURN, Mass. and JAVENÉ, France, Sept. 8, 2021 /PRNewswire/ Today, Eirion Therapeutics, Inc., an aesthetic dermatology company headquartered in Woburn, Massachusetts, announced that HTL Biotechnology, the worldwide leader in biotechnology solutions using hyaluronic acid and […]
Eirion Therapeutics Announces Strategic Agreement with HTL Biotechnology Read More »






